
Therapixel is a leading french software company specialized in artificial intelligence for medical imaging. Our aim is to develop a digital radiologist achieving the performance of best experts. Our AI is dedicated to breast cancer screening. That algorithm won the Digital Mammography DREAM Challenge, the largest Artificial Intelligence challenge ever organized. In its early years, Therapixel developed images visualization software for surgeons to make image access easier and faster from patient consultation to the operating room thanks to gesture control and intuitive user interfaces.

Therapixel is a leading french software company specialized in artificial intelligence for medical imaging. Our aim is to develop a digital radiologist achieving the performance of best experts. Our AI is dedicated to breast cancer screening. That algorithm won the Digital Mammography DREAM Challenge, the largest Artificial Intelligence challenge ever organized. In its early years, Therapixel developed images visualization software for surgeons to make image access easier and faster from patient consultation to the operating room thanks to gesture control and intuitive user interfaces.
Core product: MammoScreen — AI for breast cancer screening (CE marked, FDA 510(k) clearances)
Founded: 2013 (spun out of INRIA research)
Recent funding: €15M Series B announced May 2022
Headcount: ~61 employees (reported)
Breast cancer screening and medical imaging workflow efficiency
2013
Medical Equipment Manufacturing
€5M
€15M
Announced to accelerate MammoScreen 2D/3D deployment
“Company has backing from multiple institutional investors including Omnes, CapHorn, Crédit Mutuel Innovation, Verve Ventures, Turenne Groupe / Sham Innovation Santé, M Capital, Région Sud Investissement, IT‑Translation and others.”
| Company |
|---|